Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Inspection Record
Brookfield Medical/Surgical Supply, Inc. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Procedures designed to prevent microbiological contamination of drug products purport ing to be sterile are not followed.
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.
There are no written procedures for production and process controls designed to assure that the chug products have the identity, strength, quality, and purity they purport or are represented to possess.
Each lot of a component that is liable to microbiological contamination that is objectionable in view of its intended use is not subjected to microbiological tests before use.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
The firm has failed to collect retain samples for any of the finished drug products (Triamcinolone Acetonide, Methylprednisolone Acetate and Betamethasone Sodium Phosphate) that have been manufactured since the firm began operations in 2015.
You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2).
About this record
Extracted automatically from the document US FDA published on 2019-04-30. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
